Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CAO Ryan M. Bartolucci sold 1,858 shares of the company's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $67.57, for a total value of $125,545.06. Following the sale, the chief accounting officer now owns 55,379 shares in the company, valued at $3,741,959.03. The trade was a 3.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Tempus AI Stock Down 1.6 %
Shares of TEM traded down $1.11 on Monday, hitting $67.85. 13,615,958 shares of the stock traded hands, compared to its average volume of 11,833,515. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The business has a 50 day simple moving average of $44.49 and a 200 day simple moving average of $49.16. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $79.49.
Institutional Investors Weigh In On Tempus AI
Large investors have recently added to or reduced their stakes in the stock. First Horizon Advisors Inc. purchased a new position in shares of Tempus AI during the 3rd quarter worth $30,000. Farther Finance Advisors LLC purchased a new position in shares of Tempus AI during the 4th quarter worth $34,000. FNY Investment Advisers LLC purchased a new position in shares of Tempus AI during the 4th quarter worth $67,000. IFP Advisors Inc purchased a new position in shares of Tempus AI during the 4th quarter worth $76,000. Finally, US Bancorp DE purchased a new position in shares of Tempus AI during the 4th quarter worth $80,000. Institutional investors own 24.22% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on the company. Loop Capital lowered their price target on Tempus AI from $57.00 to $52.00 and set a "buy" rating on the stock in a research report on Tuesday, January 14th. TD Cowen reaffirmed a "buy" rating and set a $74.00 target price (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Needham & Company LLC reissued a "buy" rating and issued a $56.00 price objective on shares of Tempus AI in a research note on Tuesday, January 14th. Wolfe Research began coverage on Tempus AI in a report on Friday, December 13th. They set an "outperform" rating and a $60.00 price objective for the company. Finally, Guggenheim assumed coverage on Tempus AI in a report on Monday, December 9th. They set a "buy" rating and a $74.00 price objective for the company. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $58.55.
View Our Latest Report on TEM
About Tempus AI
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
See Also
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
